Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy

Shiven B. Patel, Ivana Gojo, Michael L. Tidwell, Edward A. Sausville, Maria R. Baer

Research output: Contribution to journalArticle

Abstract

Imatinib mesylate and other tyrosine kinase inhibitors (TKIs) that inhibit BCR-ABL have had a favorable impact on the treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). TKIs are generally well tolerated, but they can induce platelet dysfunction, which is of particular concern in the setting of thrombocytopenia in patients with acute leukemia. We present three patients with Ph+ALL receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy who developed subdural hematomas (SDHs). All three were thrombocytopenic and had undergone repeated lumbar punctures for prophylact c intrathecal chemotherapy, but they were not coagulopathic and did not have meningeal leukemia. SDHs occurred in three of a total of 10 adult patients with Ph+ALL receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy at our institution from 2007 to 2010, but in none of 22 adult patients with Ph - ALL receiving the same therapy without imatinib mesylate (p

Original languageEnglish (US)
Pages (from-to)1211-1214
Number of pages4
JournalLeukemia and Lymphoma
Volume52
Issue number7
DOIs
StatePublished - Jul 2011
Externally publishedYes

Fingerprint

Philadelphia Chromosome
Subdural Hematoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Drug Therapy
Protein-Tyrosine Kinases
Leukemia
Spinal Puncture
Thrombocytopenia
Blood Platelets
Imatinib Mesylate
Therapeutics

Keywords

  • imatinib mesylate
  • Philadelphia chromosome-positive acute lymphoblastic leukemia
  • subdural hematoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy. / Patel, Shiven B.; Gojo, Ivana; Tidwell, Michael L.; Sausville, Edward A.; Baer, Maria R.

In: Leukemia and Lymphoma, Vol. 52, No. 7, 07.2011, p. 1211-1214.

Research output: Contribution to journalArticle

@article{e3241e8461dd4eac852e000ccacb3580,
title = "Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy",
abstract = "Imatinib mesylate and other tyrosine kinase inhibitors (TKIs) that inhibit BCR-ABL have had a favorable impact on the treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). TKIs are generally well tolerated, but they can induce platelet dysfunction, which is of particular concern in the setting of thrombocytopenia in patients with acute leukemia. We present three patients with Ph+ALL receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy who developed subdural hematomas (SDHs). All three were thrombocytopenic and had undergone repeated lumbar punctures for prophylact c intrathecal chemotherapy, but they were not coagulopathic and did not have meningeal leukemia. SDHs occurred in three of a total of 10 adult patients with Ph+ALL receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy at our institution from 2007 to 2010, but in none of 22 adult patients with Ph - ALL receiving the same therapy without imatinib mesylate (p",
keywords = "imatinib mesylate, Philadelphia chromosome-positive acute lymphoblastic leukemia, subdural hematoma",
author = "Patel, {Shiven B.} and Ivana Gojo and Tidwell, {Michael L.} and Sausville, {Edward A.} and Baer, {Maria R.}",
year = "2011",
month = "7",
doi = "10.3109/10428194.2011.566950",
language = "English (US)",
volume = "52",
pages = "1211--1214",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy

AU - Patel, Shiven B.

AU - Gojo, Ivana

AU - Tidwell, Michael L.

AU - Sausville, Edward A.

AU - Baer, Maria R.

PY - 2011/7

Y1 - 2011/7

N2 - Imatinib mesylate and other tyrosine kinase inhibitors (TKIs) that inhibit BCR-ABL have had a favorable impact on the treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). TKIs are generally well tolerated, but they can induce platelet dysfunction, which is of particular concern in the setting of thrombocytopenia in patients with acute leukemia. We present three patients with Ph+ALL receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy who developed subdural hematomas (SDHs). All three were thrombocytopenic and had undergone repeated lumbar punctures for prophylact c intrathecal chemotherapy, but they were not coagulopathic and did not have meningeal leukemia. SDHs occurred in three of a total of 10 adult patients with Ph+ALL receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy at our institution from 2007 to 2010, but in none of 22 adult patients with Ph - ALL receiving the same therapy without imatinib mesylate (p

AB - Imatinib mesylate and other tyrosine kinase inhibitors (TKIs) that inhibit BCR-ABL have had a favorable impact on the treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). TKIs are generally well tolerated, but they can induce platelet dysfunction, which is of particular concern in the setting of thrombocytopenia in patients with acute leukemia. We present three patients with Ph+ALL receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy who developed subdural hematomas (SDHs). All three were thrombocytopenic and had undergone repeated lumbar punctures for prophylact c intrathecal chemotherapy, but they were not coagulopathic and did not have meningeal leukemia. SDHs occurred in three of a total of 10 adult patients with Ph+ALL receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy at our institution from 2007 to 2010, but in none of 22 adult patients with Ph - ALL receiving the same therapy without imatinib mesylate (p

KW - imatinib mesylate

KW - Philadelphia chromosome-positive acute lymphoblastic leukemia

KW - subdural hematoma

UR - http://www.scopus.com/inward/record.url?scp=79959589199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959589199&partnerID=8YFLogxK

U2 - 10.3109/10428194.2011.566950

DO - 10.3109/10428194.2011.566950

M3 - Article

C2 - 21534873

AN - SCOPUS:79959589199

VL - 52

SP - 1211

EP - 1214

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 7

ER -